Single-centre Study Investigating the Role of Long-acting Subcutaneous Glucose-dependent Insulinotropic Polypeptide Receptor Agonist (GIP RA) in Combination With Long-acting Subcutaneous Amylin Receptor Agonist on Gastrointestinal Tolerability in Participants With Overweight or Obesity
Latest Information Update: 22 Feb 2026
At a glance
- Drugs Cagrilintide (Primary) ; NNC0480-0389 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
Most Recent Events
- 22 Feb 2026 New trial record